News and Announcements
Intermin Resources (ASX: IRC) Adds $1.11m to its Cash Position from Options Exercised
- Published July 04, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Intermin Resources Limited (ASX: IRC) is pleased to advise that today it has completed the issue of 8,044,968 fully paid ordinary shares after receiving final option exercise forms and payments totalling $603,373.
KEY TAKEAWAYS:
- The new shares relate to options, exercisable at 7.5¢ and expiring on 30 June 2017, issued as part of a non-renounceable entitlement offer in July 2015.
- A total of 14,819,669 or 76.1% of these options were exercised by holders adding $1,111,475 to the Company’s cash reserves.
- The balance lapsed on 30 June 2017.
The Company’s capital structure following the exercise of the listed options is now as follows:
Listed Shares 218,412,952 Fully Paid Ordinary
Listed Options 23,674,747 (IRCOA) Exercise Price $0.17, Expiry 31 August 2018
Unlisted Options 1,750,000 (IRCAI) Exercise Price $0.125, Expiry 31 July 2018
Unlisted Options 5,000,000 (IRCAI) Exercise Price $0.075, Expiry 31 July 2018
Commenting on the option exercise, Intermin Managing Director Jon Price said:
“We thank holders for their continued support which, together with ongoing cash flow from our Teal Gold Mine, places the Company in a strong financial position to deliver on its strategy of self-funding future mine developments, consolidating assets in the Western Australian Goldfields, growing our existing Resource base and continuing the search for the next new gold discovery,” An ASX Appendix 3B Application for Quotation of Additional Securities is attached in relation to the final securities issued.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
